New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTeduglutide vs Survodutide

Teduglutide vs Survodutide

Side-by-side comparison of key properties, dosing, and research.

Recovery & Repair
Teduglutide
GLP-1 / Weight Loss Agonists
Survodutide
Summary
Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
Half-Life
~2 hours; once-daily dosing due to gut-specific residence
~7 days
Admin Route
SubQ
SubQ
Research
Typical Dose
0.05 mg/kg/day
0.6 mg → 2.4 mg → 4.8 mg → 6 mg
Frequency
Once daily
Once weekly
Key Benefits
  • Increases intestinal villus height and absorption surface area
  • Reduces intestinal permeability (leaky gut)
  • FDA-approved for short bowel syndrome
  • Reduces parenteral nutrition dependence in SBS patients
  • Promotes intestinal mucosal healing in IBD
  • Increases tight junction proteins ZO-1 and occludin
  • Up to 18.7% body weight reduction at 46 weeks (Phase 2)
  • Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
  • Reduces hepatic fat content via glucagon receptor-driven liver oxidation
  • Once-weekly subcutaneous injection
  • Greater weight loss potential than GLP-1 monotherapy
  • Improvements in liver fibrosis markers in early data
Side Effects
  • Injection site reactions
  • Abdominal pain and bloating
  • Nausea
  • Risk of intestinal polyp growth (requires colonoscopy surveillance)
  • +1 more
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +3 more
Stacks With